Literature DB >> 11393561

Psychological and ethical aspects of prevention trials.

R Roth1.   

Abstract

Advances in immunological and genetic tests and in therapeutics may soon make it possible to predict, prevent or delay the development of type 1 diabetes mellitus (DM). Psychological support should be available at every stage of the screening and prevention process for high-risk individuals. Each step in this process results in a threat to the affected individual and his/her family, followed by anxiety, decision processes, uncertainty, conflicts and depression, and also attempts to cope with these. At the first step, information about the screening procedure is provided, and an attempt is made to motivate individuals and families to take part. At the second step, there is notification of risk and, for the small group of marker-positive individuals, an invitation to participate in a prevention trial. At the third step, the individuals included in a prevention protocol have to deal with anxiety over receiving placebo, maintain cooperation with therapy, and cope with potential failures of the prevention. There are only a few psychological data gained in DM screening or intervention studies, showing high clinical anxiety while screening, both before and after notification of risk. After a few months of anxiety, it usually drops to normal levels, but family functioning seems to be changed. Data are explained within the framework of an extended Health Belief Model. Data regarding the psychological impact on family members and identification of variables related to continued study participation are needed for studies seeking to recruit and retain subjects in longitudinal protocols for prediction and prevention of type 1 DM.

Entities:  

Mesh:

Year:  2001        PMID: 11393561     DOI: 10.1515/jpem.2001.14.s1.669

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  8 in total

Review 1.  Psychological impact of screening and prediction in type 1 diabetes.

Authors:  Suzanne Bennett Johnson
Journal:  Curr Diab Rep       Date:  2011-10       Impact factor: 4.810

Review 2.  Prediabetes in children: natural history, diagnosis, and preventive strategies.

Authors:  Petri Kulmala
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Maternal anxiety about a child's diabetes risk in the TEDDY study: the potential role of life stress, postpartum depression, and risk perception.

Authors:  Roswith Roth; Kristian Lynch; Barbro Lernmark; Judy Baxter; Tuula Simell; Laura Smith; Ulrica Swartling; Anette-G Ziegler; Suzanne B Johnson
Journal:  Pediatr Diabetes       Date:  2014-08-01       Impact factor: 4.866

4.  The ethics of type 1 diabetes prediction and prevention research.

Authors:  Lainie Friedman Ross
Journal:  Theor Med Bioeth       Date:  2003

5.  Parental monitoring for type 1 diabetes in genetically at-risk young children: The TEDDY study.

Authors:  Laura B Smith; Kristian F Lynch; Kimberly A Driscoll; Suzanne Bennett Johnson
Journal:  Pediatr Diabetes       Date:  2021-04-19       Impact factor: 3.409

6.  From genetic risk awareness to overt type 1 diabetes: parental stress in a placebo-controlled prevention trial.

Authors:  Eszter Goldstein; Robert Hermann; Timo J Renfors; Kirsti M Näntö-Salonen; Tapio Korhonen; Maarit Kärkkäinen; Riitta K Veijola; Mikael Knip; Tuula T Simell; Olli G Simell
Journal:  Diabetes Care       Date:  2009-09-14       Impact factor: 19.112

7.  Parental Estimation of Their Child's Increased Type 1 Diabetes Risk During the First 2 Years of Participation in an International Observational Study: Results From the TEDDY study.

Authors:  Ulrica Swartling; Kristian Lynch; Laura Smith; Suzanne Bennett Johnson
Journal:  J Empir Res Hum Res Ethics       Date:  2016-05-30       Impact factor: 1.978

8.  Factors associated with maternal-reported actions to prevent type 1 diabetes in the first year of the TEDDY study.

Authors:  Laura B Smith; Kristian F Lynch; Judith Baxter; Barbro Lernmark; Roswith Roth; Tuula Simell; Suzanne Bennett Johnson
Journal:  Diabetes Care       Date:  2013-09-16       Impact factor: 17.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.